Work

Efficacy, Safety, LDL Cholesterol Lowering, and 10-Year ASCVD Risk Reduction: Alirocumab and Evolocumab in Addition to Maximal Tolerated LDL Lowering

Year: 2017

Type: article

Source: Journal of clinical lipidology

DOI: 10.1016/j.jacl.2017.04.050

Authors: Kenneth D'Souza, Matan Rothschild, Vybhav Jetty, Uzoma Anaba, Sarah Min, Naila Goldenberg, Ping Wang, Charles Glueck

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2612490682

FWCI:

Cites:

Cited by:

Related to: 10